ENDRA Life Sciences Management
Management criteria checks 2/4
ENDRA Life Sciences' CEO is Alex Tokman, appointed in Aug 2024, has a tenure of less than a year. directly owns 0.001% of the company’s shares, worth $32.16. The average tenure of the management team and the board of directors is 0.4 years and 9.5 years respectively.
Key information
Alex Tokman
Chief executive officer
US$103.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.0009% |
| Management average tenure | less than a year |
| Board average tenure | 9.5yrs |
Recent management updates
Recent updates
ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks
Sep 29ENDRA Life Sciences receives European patent for TAEUS system
Aug 24Endra Life Sciences Q2 2022 Earnings Preview
Aug 12We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Aug 08
We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Nov 18We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully
Jul 19ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer
Jun 15ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology
Jan 13ENDRA Life Sciences renews GE Healthcare collaboration agreement
Dec 21Endra Life prices $5M-share offering
Dec 16Endra Life Sciences EPS beats by $0.02
Nov 16CEO
Alex Tokman (62 yo)
less than a year
Tenure
US$103,347
Compensation
Mr. Alexander Y. Tokman, also known as Alex, serves as an Acting CEO and Director at ENDRA Life Sciences Inc. from August, 2024 also its Chairman. He serves as Independent Director at Izotropic Corporation...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO & Chairman | less than a year | US$103.35k | 0.00093% $ 32.2 | |
| Chief Technology Officer | 18yrs | US$531.98k | 0.0037% $ 129.0 | |
| Co-Founder | no data | no data | no data | |
| CFO & Secretary | less than a year | no data | no data | |
| Human Resources Leader | 7.7yrs | no data | no data | |
| Head of Regulatory & Clinical Affairs | less than a year | no data | no data |
0.4yrs
Average Tenure
57yo
Average Age
Experienced Management: NDRA's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO & Chairman | 17yrs | US$103.35k | 0.00093% $ 32.2 | |
| Independent Director | 12yrs | US$75.75k | 0.011% $ 380.0 | |
| Independent Director | 9.5yrs | US$73.57k | 0.00037% $ 12.8 | |
| Independent Director | 4.8yrs | US$65.07k | 0.00019% $ 6.6 | |
| Scientific Advisor | 9.4yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | 5yrs | no data | no data |
9.5yrs
Average Tenure
59.5yo
Average Age
Experienced Board: NDRA's board of directors are considered experienced (9.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 01:07 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ENDRA Life Sciences Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Kyle Bauser | Colliers Securities |